)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vincerx Pharma
Vincerx Pharma (VINC) investor relations material
Vincerx Pharma has been otc
Vincerx Pharma Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy Filing summary16 Jul, 2025
Executive summary
Special meeting to approve liquidation and dissolution has been adjourned to August 27, 2025 to allow more time for vote solicitation.
Estimated distribution to stockholders is revised to $0.03–$0.07 per share, subject to change based on timing and approval.
Delays in approval will increase operating costs and may further reduce or eliminate distributions.
Timely approval may allow U.S. stockholders to recognize a capital loss for tax purposes.
Voting matters and shareholder proposals
Stockholders are urged to vote immediately in favor of the Dissolution Proposal.
Every vote is required for the proposal to pass; instructions provided for phone and internet voting.
Board of directors unanimously recommends approval of the Dissolution Proposal.
Board of directors and corporate governance
Board's rationale for recommending dissolution includes maximizing potential distributions and tax benefits.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vincerx Pharma
- Shelf registration enables up to $100M in securities offerings for corporate and pipeline needs.VINC
Registration Filing - Auditor flags going concern risk as securities are registered for flexible public offering.VINCRegistration Filing
- Proposed merger gives Oqory 95% ownership and advances late-stage ADC pipeline, pending approvals.VINCProxy Filing
- Shareholders will vote on repricing and exchanging underwater stock options to boost retention.VINCProxy Filing
- Board seeks approval for dissolution, with no expected distributions to stockholders.VINCProxy Filing
- Shareholders will vote on a program to reprice options and exchange them for RSUs with new vesting.VINCProxy Filing
- Amendment raises minimum stockholder value to $14.16M and waives $500K interim financing.VINCProxy Filing
- Stockholders are urged to approve dissolution on June 18, 2025, to maximize distributions.VINCProxy Filing
- Proposed merger advances anti-TROP2 ADC, with Oqory to hold 95% post-merger and $20M financing required.VINCProxy Filing
- Stockholders will vote on a one-time stock option repricing and exchange program for employees.VINCProxy Filing
Vincerx Pharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company engaged in the development of therapies designed to address unmet medical needs in cancer treatment. Their research focuses on creating new treatment options through the development of drugs like enitociclib, a cyclin-dependent kinase-9 inhibitor currently in clinical trials for patients with hematologic malignancies. Another key area of their research involves VIP236, a small molecule drug conjugate, also in trials, targeting solid tumors. Additionally, Vincerx Pharma is exploring product candidates such as VIP943 and VIP924 for treating hematologic malignancies. The company is headquartered in Palo Alto, California, and its shares are listed on the Nasdaq.